KindredBio Leadership

Richard Chin, MD

Richard Chin, MD

Co-Founder and Chief Executive Officer

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.

Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.

Denise Bevers

Denise Bevers

Co-Founder, President, and Chief Operating Officer

Denise Bevers is an experienced pharmaceutical executive with a distinguished career in clinical operations, medical affairs, and scientific communications. With over 20 years of pharmaceutical and research experience, she has successfully managed dozens of product launches and development programs from phase I through IV. Ms. Bevers previously held leadership positions at Elan Pharmaceuticals, Scripps Clinic and Research Foundation, Quintiles, and SkyePharma. Prior to co-founding KindredBio, she was president and founding partner of SD Scientific, a full-service medical affairs and communications company.

Wendy Wee

Wendy Wee

Chief Financial Officer

Wendy Wee is a financial executive with over 30 years of public company experience in both the biotechnology and high-tech industries. From 2002 to 2014, Wendy served in various positions at Telik — a biotechnology company focused on oncology — including vice president of finance, principal financial and accounting officer, and controller. Prior to Telik, Wendy was the senior director of finance and controller at Connetics, Inc., a biotechnology company focused on dermatological diseases. Before Connetics, she held various management positions at companies like Silicon Graphics, Inc., MIPS Computer Systems, and Unisys Corporation.

Hangjun Zhan, PhD

Hangjun Zhan, PhD

Chief Scientific Officer

Dr. Zhan is a highly regarded protein biochemist and biophysicist with 20 years of drug discovery experience in the biotech industry. He joined KindredBio in February 2014 to lead biologics research. Previously, Dr. Zhan served as an executive member at Aragen Biosciences and led their protein sciences group. Prior to that, he established and headed up the Protein Biochemistry Group at Exelixis, including protein expression, fermentation/bioproduction, protein purification/biophysics, and proteomics. His team’s work led to more than 20 drug candidates. He has also previously served as group leader of Protein Chemistry at Axys Biopharmaceuticals (Celera) where he managed a fermentation group and a protein biochemistry group. Dr. Zhan completed his post-doctoral training in Dr. John Collier’s lab at Harvard Medical School; there, he applied in-depth biophysics to elucidate dynamic protein structural changes in solution and in membrane. While earning his Ph.D. from the University of Washington, he discovered a novel chemical-signaling molecule involved in bacterial invasion.

Jenna (Hahn) Mutch

Jenna (Hahn) Mutch

Vice President of Commercial

Specializing in the companion animal and equine industries, Jenna Hahn has over 15 years of sales, marketing, and product launch experience. Jenna has worked in the veterinary division of Hill’s Pet Nutrition and Merck and for animal health companies such as Merial and IDEXX. She has consulted for many small businesses in the pet and equine industry, helping to bring their products to the veterinary market. She currently sits on the board of directors for the Northern California Association of Equine Practitioners. Jenna is very active in the veterinary community and has spent her career working directly with veterinarians and their staffs to help improve the quality of life for the animals we love.

Katja Buhrer

Katja Buhrer

Vice President of Corporate Development and Investor Relations

Katja Buhrer has a diverse background in investor relations advisory, capital markets, and financial reporting. Before joining KindredBio, she was managing director at the investor relations consultancy MBS Value Partners. In this role, Katja devised and executed investor relations programs for the firm’s clients and oversaw their investment community communications. Previously, Katja worked at Citi in capital markets and sales and trading. She was also a reporter, editor, and columnist at the Australian Financial Review. During this time, Katja was a frequent author of front-page stories, reported on Australia’s largest companies, and had a personal weekly capital markets column.

Om Srivastava, Ph.D.

Om Srivastava, Ph.D.

Vice President of Pharmaceutical Development

Dr. Srivastava is KindredBio vice president and head of pharmaceutical development, overseeing the drug development process from inception to commercialization. He has over 20 years of experience in pharmaceutical development, CMC, biologics, and more.

Prior to KindredBio, Dr. Srivastava was the director of pharmaceutical product development at Mirati Therapeutics where he led pharmaceutical development and oncology programs. Previously, he was an associate director at Optimer Pharmaceuticals, responsible for the development of small molecules as novel antibiotics and biologics. He served as the program director for nutraceuticals and pharmaceuticals at Alberta Research Council and was awarded as the 1st Distinguished Scientist in the Province of Alberta for his contributions. Dr. Srivastava earned his Ph.D. in organic chemistry from Lucknow University and was an Alberta Heritage Foundation for Medical Research (AHFMR) fellow at the University of Alberta in Edmonton, Alberta, Canada.

Karen Greenwood

Karen Greenwood

Vice President of Project Management

Karen Greenwood has 30 years of experience in animal health drug discovery and development. She is a biochemist by training, with 15 years of laboratory experience in screen design and development. She previously worked at Pfizer Animal Health, Zoetis, and Parnell, giving her broad experience across companion animal and livestock projects and both small molecules and monoclonal antibodies. Karen is familiar with all stages of the drug discovery process, from idea to proof of concept, from clinical studies, regulatory submission, and launch to marketing. She is particularly proud of her work on Apoquel and Cytopoint for atopic dermatitis in dogs.

Melinda Poole O’Banion, DVM

Melinda Poole O’Banion, DVM

Executive Director of Clinical Development and Regulatory Affairs

Melinda Poole O’Banion is an equine internal medicine specialist. She trained in an American College of Veterinary Internal Medicine and American Board of Veterinary Practitioners residency program at Mississippi State University College of Veterinary Medicine where she also served as clinical teaching faculty for two years. Post academia, she transitioned into the animal health industry in clinical research and development, working on novel drugs for dogs, cats, and horses. Melinda was previously at Boehringer Ingelheim Vetmedica, Elanco Animal Health, and Dechra Veterinary Products. She was the key clinical development member for Prascend (pergolide) for horses and Osphos (clodronate injection) for horses. Melinda has 14 years of animal health industry experience developing drugs for animals; she has worked on numerous small molecules for dogs, cats, and horses in early- and late-stage development.

Kathy Vannatta

Kathy Vannatta

Senior Director, Regulatory Affairs

Kathy Vannatta has over 20 years of experience in animal health regulatory affairs and research and development. She previously worked at Elanco Animal Health where she was a proven leader and regulatory professional supporting both companion and food animal development. She has gained key product approvals with both the FDA and EPA. Kathy is experienced with mergers and acquisitions and has expert knowledge in global regulatory affairs transition strategies. Kathy is passionate about how regulatory affairs can enable innovation that allows dogs, cats, and horses to live longer, healthier lives.